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ABSTRACT
Background Guidance for public health management of invasive meningococcal disease (IMD) in in England recommends the use of antibiotic
chemoprophylaxis and vaccination. We summarized clinical and epidemiological data collected during routine management of IMD clusters in
England.
Methods Data on epidemiology and operational decisions for public health management were reviewed for clusters between April 2010 and
December 2015.
Results Clusters were generally 2–3 cases (53/58; 91%) within a single age band <18-years. Nurseries (n = 20, 34%), households/social
networks (n = 14, 24%) and schools (n = 10, 17%) were the commonest settings. Chemoprophylaxis alone was used in 36 (58%) clusters,
including most serogroup B clusters (31/41; 76%). Chemoprophylaxis and vaccination was used in a further 20 (32%) clusters. Vaccine was
delivered promptly (<7 days). Four clusters had cases with onset post-chemoprophylaxis; no clusters recorded cases with onset post-vaccination.
No pattern was observed between interventions and setting/population at risk, and interventions were consistent with national guidance.
Challenges to management included logistical issues related to intervention delivery.
Conclusions Public health management of IMD clusters presents challenges in decision-making and implementation of interventions.
Nonetheless, few cases were observed following intervention. Responses were consistent with national guidance. A systematic data collection
tool should be developed to support future evaluation.
Introduction
Invasive meningococcal disease (IMD), caused by infection
with Neisseria meningitidis, commonly presents as meningitis,
septicaemia and other localized invasive presentations.1 The
combination of a high case fatality rate (9% for Europe in
2014)2 and considerable risk of long-term sequelae1 generate
substantial public concern for just a single case, requiring
focused public health management and risk communication.
Microbiological characterization into serogroups is based on
identiﬁed capsular groups (which A, B, C, W, X and Y are
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the most common) with further differentiation by molecular
sequence typing.3
Following introduction of the meningococcal C (MenC)
conjugate vaccine into the UK routine immunization pro-
gramme for children in November 1999, conﬁrmed cases of
IMD caused by serogroup C meningococcus fell dramatic-
ally; both directly, by over 90% in immunized age groups,
and indirectly, by two-thirds in other age groups due to
reduced carriage and exposure.4 The impact of the introduc-
tion of the MenC vaccine in England has also been a reduc-
tion in overall IMD incidence with rates remaining relatively
stable since (~1 per 100 000 persons), and the greatest bur-
den of disease amongst those aged <1 year and 1–4 years.5
However, over time, the UK has observed a shift in domin-
ance to serogroup B and the emergence of serogroup W,5
leading to the replacement of MenC vaccines in the routine
infant schedule with a serogroup B vaccine (MenB), and the
introduction of a vaccine covering serogroups A, C, W and
Y (MenACWY) as an adolescent dose in 2014.6
For most, carriage of N. meningitidis in the nasopharynx is
an asymptomatic event that leads to a systemic protective
antibody response,7 with prevalence peaking in young adults.8
Transmission is via respiratory aerosol or droplets, and
requires substantial contact with a carrier.9 Consequently, set-
tings where such contact levels occur—living in a ‘closed’ or
‘semi-closed’ community (e.g. residential halls or military bar-
racks)—are recognized risk factors for IMD.10 Transmission
from an asymptomatic carrier within the household setting is
the most likely route of acquisition for cases of IMD,11,12
although almost all (>95%) cases in in England and Wales
have no recognized transmission links.13 Household contacts
are at highest risk of during the ﬁrst 7 days after onset of ill-
ness in the index case13 with a low risk for contacts outside
of the household.14,15
Chemoprophylaxis of household contacts with antibiotics
remains the single most effective control measure, through
the eradication of the organism from established carriers and
from those who may have newly acquired an invasive strain
but have yet to progress to infection.9,16 In the UK, vaccines
are available as potential additional interventions for close
contacts of IMD cases to reduce the long-term risk of dis-
ease.9 This includes the use of the MenC and MenACWY
vaccines and, more recently, the MenB vaccine.17 However,
there remains a need for a stronger evidence-base for the
effectiveness of these interventions.9,16,17
As part of the routine public health response to IMD
clusters, Public Health England (PHE) collects and records
clinical and epidemiological details of IMD cases, the popu-
lation at risk and vaccine uptake. However, data collection is
not standardized or mandated. Through a review of
information collected for the investigation of IMD clusters
in England, we describe the epidemiology and management
of clusters in England over a 5-year period and provide
insights into the challenges associated with effective
management.
Methods
Data collection
Since April 2010, data on IMD cases and clusters in England
has been captured on an electronic case and incident manage-
ment system (HPZone). Data was extracted from HPZone
for all clusters of IMD entered between 1 April 2010 and
21 December 2015. Data was collected on the epidemiology
of the cluster (number of cases according to diagnostic conﬁ-
dence, age and onset date of cases, meningococcal serogroup,
setting and population at risk) and public health management
(use of vaccination, including vaccine used and delivery; use
of chemoprophylaxis, including antibiotics used and delivery;
number eligible and number receiving vaccination and/or
chemoprophylaxis; details of decision-making for use of
vaccination/chemoprophylaxis) (Supplementary Table S1).
Information on the management of clusters was derived
from 18 separate data ﬁelds.
Case and cluster deﬁnitions
Possible case
A clinical diagnosis of meningitis, septicaemia or other inva-
sive disease where the lead public health practitioner, in con-
sultation with a clinician and/or microbiologist, considered
that diagnoses other than meningococcal disease were at
least as likely.
Probable case
A clinical diagnosis of meningitis, septicaemia or other inva-
sive disease where the lead public health practitioner, in con-
sultation with the physician and microbiologist, considered
that meningococcal infection was the most likely diagnosis.
Conﬁrmed case
A clinical diagnosis of meningitis, septicaemia or other inva-
sive disease and at least one of: N. meningitidis isolated from
a normally-sterile site, Gram-negative diplococci present in a
normally-sterile site, meningococcal DNA detected in a
normally-sterile site or meningococcal antigen detected in
blood, cerebrospinal ﬂuid or urine.
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Closed or semi-closed community clusters
Two or more conﬁrmed or probable cases who attended the
same educational setting (preschool group, school, college,
university) or lived in the same residential setting (house-
hold, military barracks, asylum centre, care home) or in
other similarly deﬁned social groups that were diagnosed
within a 4-week period and were considered at the time of
public health action to be caused or likely to be caused by
the same meningococcal serogroup.
Wider community clusters
Age-speciﬁc attack-rate for a vaccine-preventable meningo-
coccal serogroup within a deﬁned geographical boundary
over a 3-month period identiﬁed as higher than expected by
the managing team and consistent with recommendations in
national guidance.9
Results
Descriptive epidemiology
There were 94 clusters of IMD recorded between 1 April
2010 and 31 December 2015, two of which extended into
2016. Sixty-two (66%) required public health management
and were used as the denominator for the description of
public health management. Of these clusters, four were lat-
terly excluded due to either a lack of microbiological evi-
dence to support linkage or discarding of a case that no
longer met one of the IMD deﬁnitions. Of the 32 clusters
that did not require public health management, 23 were not
considered for intervention due to information obtained
after reporting that meant they no longer met the cluster
deﬁnition, three were single cases and six were duplicate
entries. A total of 58 clusters were included in the descriptive
epidemiological analysis (Table 1) (Supplementary Figure).
Table 1 Clusters of invasive meningococcal disease by year, age group of cases, contextual setting and serogroup
Characteristic Clusters by year Total
2010a 2011 2012 2013 2014 2015
All clusters 9 11 13 10 6 9 58
Age group
<1 year only 0 1 0 1 0 0 2
1–4 years only 4 3 5 1 1 2 16
5–9 years only 0 1 1 1 0 1 4
10–17 years only 0 2 1 0 0 0 3
0–18 years only 3 1 5 3 1 2 15
≥18 years only 0 2 1 1 3 3 10
All ages 2 1 0 3 1 1 8
Contextual setting
Nursery 4 4 6 3 1 2 20
Household/social network 2 1 3 3 3b 2 14
School 1 3 3 1 0 2 10
College/university 0 2 0 0 1b 3 6
Community 1 1 0 1 1 0 4
Otherc 1 0 0 1 0 0 2
Care home 0 0 0 1 1 0 2
Hospital 0 0 1 0 0 0 1
Serogroup
B 6 11 11 6 2 4 40
C 0 0 0 0 2 2 4
W 0 0 1 2 1 1 5
Y 2 0 0 0 0 1 3
Untyped 1 0 1 2 1 1 6
aData from 1 April 2010.
bOne cluster involving two settings.
cVisitor attraction (2010) and caravan site (2013).
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There was an average of 10 (range 6–13) IMD clusters
recorded per year between 2011 and 2015 (Table 1). The
number of reported clusters mirrored the seasonal distribu-
tion of IMD cases (Spearman’s rank correlation coefﬁcient,
rs = 0.615, P = 0.001) with some geographical variation
(Fig. 1). Clusters comprised a total of 148 cases, of which
79% (n = 117) were laboratory-conﬁrmed. The majority of
clusters consisted of two (n = 39, 67%) or three (n = 14,
24%) cases; four clusters consisted of four cases and one
cluster of 12 cases.
Forty clusters (69%) consisted only of cases aged <18
years; 64% (16/25) were restricted to cases aged 1–4 years
(Table 1). A further 10 clusters consisted only of those aged
≥18 years and another eight clusters considered of cases
aged both <18 and ≥18 years. Nurseries (n = 20, 34%),
households or social networks (n = 14, 24%) and schools
(n = 10, 17%) were the most common settings (Table 1).
There were no clusters identiﬁed within the childminder
setting.
Serogroup B accounted for 69% (40/58) of clusters, with
the highest numbers of clusters reported in 2011–12 (11
each year) and then falling to an average of four clusters per
year for 2013–15. Typing information was not available for
six clusters. Of the conﬁrmed cases which were part of a
cluster, 77% (90/117) were serogroup B (Table 2). The per-
centage of laboratory-conﬁrmed cases nationally that were
within clusters (all serotypes: 117/4723, 2.5%) was similar
for serogroup B (90/3450, 2.6%) and for all other
serogroups combined (27/1273, 2.1%) (χ2 = 0.69, P =
0.407). There was no evidence of a statistically signiﬁcant
trend in the proportion of quarterly laboratory-conﬁrmed
cases that were part of clusters (Poisson regression; all ser-
ogroups, serogroup B, all other serogroups: each P > 0.05).
Fifty percent (45/90) of cases within clusters of serogroup B
were aged 1–4 years (Table 2). The vast majority of clusters
of serogroup B (88%, 35/40) involved cases aged <18 years
and 60% (24/40) were either in nurseries (n = 17) or
schools (n = 7) (Table 2).
The majority of clusters (57%; 33/58) had a duration
(interval in days between onset of the ﬁrst and last case) of
≤7 days (median = 7, range 0–151). Eight clusters extended
over 30 days and included ≥3 cases; the setting for these
clusters were nurseries (three clusters), colleges/universities
(two clusters), community increases (two clusters) and a
household/social network (one cluster). Only four clusters
included cases with onset dates reported after the date of
implementation of chemoprophylaxis; no situations recorded
cases with onset after vaccination.
Management of clusters
Use of interventions
Antibiotic chemoprophylaxis only was used as an interven-
tion for 36/62 (58%) clusters (an additional three clusters
were managed with chemoprophylaxis but information on
use of vaccines was not available) and a further 20 (32%)
Fig. 1 Laboratory-conﬁrmed cases and clusters of invasive meningococcal disease in England. Cases are those conﬁrmed at the Public Health England
Meningococcal Reference Laboratory. Q1 = January–March; Q2 = April–June; Q3 = July–September; Q4 = October–December.
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clusters were managed with a combination of chemoprophy-
laxis and vaccination (Table 3). Three clusters were not man-
aged with either chemoprophylaxis or vaccination (Table 3).
There was no clear pattern to the choice of intervention by
context or the age group of the population at risk (Table 3).
Chemoprophylaxis only was used where: typing informa-
tion was not available (four clusters), for a cluster latterly
determined not to be a true cluster, and for the majority of
serogroup B clusters (31/41, 76%). There were three ser-
ogroup B clusters (two in a nursery and one in a house-
hold/social setting) where only immediate contacts of
individual cases were managed with chemoprophylaxis.
All clusters of meningococcus serogroup C, W and Y
were managed with a combination of chemoprophylaxis and
vaccination (Table 3). Only 15% (6/41) of the serogroup B
clusters were managed with vaccination and chemoprophy-
laxis; representing ﬁve of the six clusters that occurred dur-
ing 2014–15 (i.e. after the introduction of the MenB
vaccine) and one cluster managed in 2010 (a family with
underlying immunological disease where the MenACWY
conjugate vaccine was offered to protect against other ser-
ogroups). The two serogroup B clusters that occurred after
2014 and where vaccination was not offered both occurred
in a college/university setting. The rationale for not offering
vaccination was available for one of these clusters and was
based on strain characterization of isolates from two cases
that indicated a lack of genetic relatedness.
Other interventions were employed for 14 (23%) clusters;
including information and awareness-raising to the population
Table 2 Clusters of invasive meningococcal disease by serogroup and
contextual setting and age group of cases
Characteristic Serogroup
B C W Y Not typed
Number of clusters
Contextual setting
Nursery 17 0 1 0 2
Household/social network 9 1a 1 0 3
School 7 2 0 0 1
College/university 4 1a 0 1 0
Community 2 1 0 1 0
Otherb 1 0 0 1 0
Care home 0 0 2 0 0
Hospital 0 0 1 0 0
All settings 40 4 5 3 6
Number of cases
Age group
<1 year 5 0 1 1 1
1–4 years 45 2 2 1 13
5–9 years 14 3 0 0 8
10–17 years 9 1 0 1 3
≥18 years 17 2 7 3 5
All ages 90 8 10 6 34
aOne cluster involving two settings.
bVisitor attraction (serogroup Y) and caravan site (serogroup B).
Table 3 Management of invasive meningococcal disease clusters by
serogroup, context and age group of population at risk
Characteristic Interventions Total
Chemoprophylaxis
and vaccination
Chemoprophylaxis
only
None
All situations 20 39a 3 62
Serogroup
B 6b 32c 3 41
C 6 0 0 6
W 5 0 0 5
Y 3 0 0 3
Not typed 0 6c 0 6
N/A 0 1 0 1
Contextd
Nursery 3 15 2 20
Household/
social network
6 9e 1 16
School 3 8 0 11
College/
University
2 4 0 6
Community 2 2 0 4
Other 1 1 0 2
Care Home 2 0 0 2
Hospital 1 0 0 1
Workplace 1 0 0 1
Age group
<1 year only 0 2 0 2
1–4 years only 3 12 1 16
5–9 years only 1 3 0 4
10–17 years
only
0 3 0 3
<18 years
only
6 4 0 10
≥18 years
only
3 10c 2 15
All ages 7 5c 0 12
aInformation on use of vaccination missing for three clusters.
bOne cluster managed with MenACWY vaccine.
cInformation on use of vaccination missing for one cluster.
dOne situation included two settings.
eInformation on use of vaccination missing for two clusters.
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at risk, healthcare professionals and the wider community.
One cluster at a university involved working with the local
healthcare community to deliver vaccination clinics for eligible
staff and students to improve uptake amongst the wider
population considered to be at risk.
The total number of contacts eligible for chemoprophy-
laxis was available for 80% (47/59) of clusters managed
with chemoprophylaxis. In two additional clusters only
household members were offered chemoprophylaxis but the
household size was not recorded. The size of the population
at risk ranged from 0 to 5 300 (median = 46, interquartile
range [IQR] = 13–126). The situation with 5 300 persons at
risk involved a holiday park and included not just close con-
tacts of cases but all staff and visitors on site at the same
time as the cases. For the majority of clusters where data
was available, all eligible contacts received chemoprophylaxis
(70%, 29/42). Reasons for failure to treat all eligible contacts
included absence from school, failure to attend intervention
events and refusal/lack of consent.
Delivery of interventions
Chemoprophylaxis and vaccination were delivered in a range
of settings. For chemoprophylaxis, this included the impli-
cated institution (20 clusters), the General Practice (ﬁve clus-
ters), the hospital (four clusters) and a combination of
hospital and General Practice (ﬁve clusters). Management of
two clusters involved bespoke clinics set-up to offer chemo-
prophylaxis to nurseries. Delivery of chemoprophylaxis in
the community was completed by a combination of staff
from multiple organizations, including staff from the
National Health Service, PHE and other local health organi-
zations. Of the clusters where vaccine was used and data
was available, vaccine was delivered within primary care
(57%; 7/13) or the implicated setting (43%; 6/13).
Chemoprophylaxis was implemented within 48 h (range
0–66 days) of the decision to intervene for 80% of clusters
(33/38 with available data). Two clusters reported a delay of
over 30 days: one of these involved four cases within a
household setting over a 2 month period where a diagnosis
of underlying immunological disease informed additional
control measures. The second cluster involved two probable
cases 14 days apart within a household setting where the
population at risk spanned ﬁve households.
For those clusters where data was available (11/20), the
number of contacts eligible for vaccination ranged from 0 to
188 (median = 24; IQR 10–91). Vaccine was provided
within 7 days of the decision to vaccinate for nine of the 10
situations where data were available; for four situations vac-
cination occurred within 48 h. For eight of these clusters,
the number of contacts eligible for vaccination was the same
as those eligible for chemoprophylaxis. Eligible contacts
received vaccination for seven of the nine (78%) clusters
where the number of contacts vaccinated was recorded.
Challenges to management
Both decision-making and operational challenges during
management of clusters were documented for 12 IMD clus-
ters. The major challenge was the inability to clearly deﬁne
the population at risk (for example, two cases in a school
but not in the same year group or social network). Other
documented challenges included a lack of clear eligibility for
vaccination following new guidance for meningococcal B
clusters, difﬁculty in tracing all contacts and atypical micro-
biological ﬁndings (each reported for one cluster).
Operational challenges to the delivery of interventions (22
clusters) included resource constraints (difﬁculty sourcing
vaccine or antibiotics, particularly syrup preparations; limited
nursing staff available to deliver intervention; uncertainty
about funding the intervention, speciﬁcally in one instance
where students were asked to pay for the prescription), logis-
tics (organizing a large-scale intervention within a very short
time frame), communication (rapidly and effectively contact-
ing families and obtaining consent), and having legal frame-
works in place to allow supply of medicines (Patient Group
Directions; PGD). Two of the ﬁve serogroup B clusters
managed with vaccination reported issues of sourcing and
cost of the vaccine as a challenge to delivery. Both clusters
were from 2014, and noted particular uncertainty at that
time given the new recommendations for use of the MenB
vaccine.
Where challenges to the overall management of the clus-
ter were documented (16 clusters), parental and public anx-
iety and issues of effective communication were most
commonly reported (eight clusters). Other challenges
included a lack of clarity on roles and responsibilities of key
stakeholders and where complex epidemiology of the cluster
made decisions about the need to extend management of
the cluster difﬁcult. Actions taken included developing a
suite of communications material for parents, public and
health professionals, including signposting and use of mater-
ial produced by meningitis charities. Full and frank debriefs
were also noted to be important to clarify roles and respon-
sibilities and to work through logistics for similar situations
that may occur in the future (this included developing PGD,
identifying stocks of chemoprophylaxis, and mechanisms for
obtaining large volumes of vaccine). Solutions adopted to
ensure effective delivery of interventions included the use of
smart technology (text messages to contact parents) to sup-
port rapid communication and to improve pre-completion
of consent, often supplemented by active follow-up.
6 JOURNAL OF PUBLIC HEALTH
D
ow
nloaded from
 https://academ
ic.oup.com
/jpubhealth/advance-article-abstract/doi/10.1093/pubm
ed/fdz028/5426644 by W
est Sussex Public H
ealth user on 08 April 2019
Discussion
Main ﬁndings of this study
This study describes the epidemiology and effective manage-
ment of IMD clusters in England and provides insights into
the challenges encountered during management. Clusters of
IMD most commonly occurred in closed settings such as
nurseries, schools and households, with the majority involv-
ing ≤3 cases. No clusters were reported in a childminder set-
ting and community-wide increases were very uncommon.
All but three clusters involved the provision of antibiotic
chemoprophylaxis, with or without vaccination, to the wider
population at risk, delivered within 48 h for 80% of mana-
ged clusters. Where vaccine was used, implementation
occurred within seven days for all but one cluster. Control
measures appeared effective in limiting spread: only four
clusters included cases with onset dates reported after the
date of implementation of chemoprophylaxis; no situations
recorded cases with onset after vaccination. The main docu-
mented challenges were logistical, related to the delivery of
antibiotics and vaccine.
What is already known on this topic
Clusters of IMD require timely public health action to pre-
vent further transmission, particularly the prompt vaccin-
ation of contacts. Effective public health action is primarily
through chemoprophylaxis of close contacts with antibiotics.
Vaccination is considered where typing indicates risk from a
vaccine-preventable strain, although use of vaccine is known
to have considerable resource implications.
What this study adds
Clusters of IMD were generally small (≤3 cases) affecting
children and young adults, with children aged 1–4 years
being the most affected age group. As is expected given this
age group, clusters most commonly occurred in nurseries,
schools and households. Given predominance in this age
group and within closed settings, and the known risk factors
for person-to-person transmission of N. meningitidis, it is not
unexpected that community wide increases were very
uncommon. Although serogroup B was isolated in over
two-thirds of reported clusters, the number of serogroup B
clusters decreased after 2013, with a concomitant increase in
the number of clusters due to serogroups Y, W and C.
All but three clusters involved the provision of antibiotic
chemoprophylaxis, with or without vaccination, to the wider
population at risk. A lack of systematic data collection limits
the use of current data for the evaluation of the impact of
public health interventions for IMD clusters. Challenges to
management were largely logistical, related to local
responsibilities and complexities of sourcing antibiotics, vac-
cines and staff to deliver the intervention to a very short
timescale. It is nonetheless encouraging that interventions
intended to reduce the risk of serious infection and to inter-
rupt transmission were promptly delivered.
Communication and justiﬁcation of key decisions to the
population at risk, wider members of the public and health-
care professionals, was another challenge. Refusal or failure
to accept interventions were reported as primary reasons for
sub-optimal uptake in two-thirds of clusters where data was
available. A qualitative evaluation of acceptability, knowledge
and attitudes (of both the population at risk and healthcare
professionals) may inform how information can be best
communicated and interventions delivered to maximize
uptake.
Limitations of this study
This study utilized data recorded routinely for public health
management. As such, data ﬁelds did not match the exact
requirements of their secondary use in this study. Despite
good overall completion, information was inconsistently pre-
sented or stated as not available or not clear for a number
of data ﬁelds, including the population at risk. The descrip-
tion and number of contacts within each population at risk
group was only provided in full for 27 clusters. Information
on the management of clusters was derived from 18 data
ﬁelds, with only six of these ﬁelds completed for all situa-
tions: ﬁelds that were least well completed were date of
implementation (88%), how chemoprophylaxis was delivered
(88%) and other interventions (92%). Information on how
vaccine or chemoprophylaxis was sourced and administered
was also poorly recorded. Not all household clusters of
IMD are entered onto the system, meaning that there may
be an under-representation of clusters.
Although the use of routine cluster management data pro-
vides invaluable insight into the epidemiology of clusters of
IMD, data quality limits its use in formal evaluation of the
effectiveness of vaccines in cluster management. Further
work is required to robustly evaluate the use of vaccines
(particularly, the 4CMenB [Bexsero®] vaccine), for manage-
ment of IMD clusters and to address gaps in the evidence
base. Where typing results were not available, it is possible
that clustered cases were not epidemiologically linked.
Supplementary data
Supplementary data are available at the Journal of Public
Health online.
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